EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pharmacomicrobiomics: Exploring the role of gut microbiota in type 2 diabetes and antidiabetic drug mechanisms

Dingsheng Wen, Xiangyue Wang, Yanping He, Xiaoqing Hao, Weihua Huang, Honghao Zhou, Wei Zhang, Xiong Li

Nutrition, Metabolism and Cardiovascular Diseases · 2026-02 · 36 (2) · 104379

DOI: 10.1016/j.numecd.2025.104379 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2026-02. Verfasst von Dingsheng Wen und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Clinical Pharmacy (School of Integrative Pharmacy), Guangdong Pharmaceutical University, Guangzhou, 510006, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Bacteria. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 137 Literaturangaben. Gefördert von: National Key Clinical Specialty Discipline Construction Program of China, Guangdong Medical Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIM: The gut microbiota is intricately linked to the pathogenesis of type 2 diabetes mellitus (T2DM). This review aims to explore the bidirectional interaction between antidiabetic drugs and the gut microbiota, focusing on how drugs modulate the microbiome to exert therapeutic effects and how this interaction influences common drug side effects, thereby outlining the role of pharmacomicrobiomics in personalizing T2DM treatment. METHODS AND RESULTS: We comprehensively reviewed literature from PubMed, Scopus, and Embase on gut microbiota, T2DM, and antidiabetic drugs. Evidence indicates that various drug classes (e.g., metformin, sodium glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists (RAs), α-glucosidase inhibitors (AGIs)) significantly alter gut microbial composition (e.g., Bacteroidetes - to -Firmicutes ratio), functionality, and metabolite production (e.g., SCFAs, bile acids). These changes contribute not only to glycemic control but also to the drugs' cardiorenal benefits. Conversely, the microbiota influences drug metabolism and is implicated in the manifestation of typical side effects, such as gastrointestinal disturbances from metformin and acarbose. CONCLUSIONS: The gut microbiota is a crucial mediator of both the efficacy and toxicity of antidiabetic drugs. Understanding pharmacomicrobiomics provides a novel framework for developing personalized therapeutic strategies in T2DM, potentially using an individual's microbiome as a biomarker for drug selection and side effect prediction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeDiabetes Mellitus, Type 2Hypoglycemic AgentsBacteriaBlood GlucoseIntestinesHumansAnimalsSodium-Glucose Transporter 2 InhibitorsGlycoside Hydrolase InhibitorsTreatment OutcomeDysbiosisRisk Factors

Stichwörter der Autor:innen

Antidiabetic drugsDrug-microbiota interactionGut microbiotaPersonalized medicinePharmacomicrobiomicsType 2 diabetes mellitus

Substanzen

Hypoglycemic AgentsBlood GlucoseSodium-Glucose Transporter 2 InhibitorsGlycoside Hydrolase Inhibitors

Autor:innen und Institutionen

  • School of Pharmacy, Clinical Pharmacy (School of Integrative Pharmacy), Guangdong Pharmaceutical University, Guangzhou, 510006, China.
  • Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan Province, 410078, China.
  • Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan Province, 410078, China. Electronic address: csuzhangwei@csu.edu.cn.
  • School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, 510006, China. Electronic address: lixiong@gdpu.edu.cn.

Förderung

  • National Key Clinical Specialty Discipline Construction Program of China
  • Guangdong Medical Research Foundation

Zitieren

APA

Wen, D., Wang, X., He, Y., Hao, X., Huang, W., Zhou, H., Zhang, W., & Li, X. (2026). Pharmacomicrobiomics: Exploring the role of gut microbiota in type 2 diabetes and antidiabetic drug mechanisms. Nutrition, Metabolism and Cardiovascular Diseases, 36(2), 104379. https://doi.org/10.1016/j.numecd.2025.104379

Vancouver

Wen D, Wang X, He Y, Hao X, Huang W, Zhou H, et al. Pharmacomicrobiomics: Exploring the role of gut microbiota in type 2 diabetes and antidiabetic drug mechanisms. Nutrition, Metabolism and Cardiovascular Diseases. 2026;36(2):104379. doi:10.1016/j.numecd.2025.104379

BibTeX
@article{Wen2026,
  author = {Wen, Dingsheng and Wang, Xiangyue and He, Yanping and Hao, Xiaoqing and Huang, Weihua and Zhou, Honghao and Zhang, Wei and Li, Xiong},
  title = {Pharmacomicrobiomics: Exploring the role of gut microbiota in type 2 diabetes and antidiabetic drug mechanisms},
  journal = {Nutrition, Metabolism and Cardiovascular Diseases},
  year = {2026},
  volume = {36},
  number = {2},
  pages = {104379},
  doi = {10.1016/j.numecd.2025.104379}
}
Kostenlos starten →